Shanghai Henlius Biologics Co. Ltd., Shanghai Henlius Biopharmaceutical Co. Ltd. and Shanghai Henlius Biotech Inc. have disclosed new antibody-drug conjugates comprising a monoclonal antibody targeting HER2 covalently linked to a camptothecin derivative potentially useful for the treatment of cancer.